Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
10 minute read
  • Earnings

Earnings Scheduled For March 9, 2023

By Benzinga Insights
March 9, 9:00 AM
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.

ACHR

Read More
1 minute read
  • Earnings
  • News

Acorda Therapeutics Q4 EPS $(0.57) Up From $(1.73) YoY, Sales $31.47M Down From $36.97M YoY

By Benzinga Newsdesk
March 9, 8:02 AM
Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(0.57) per share. This is a 67.05 percent increase over losses of $(1.73) per share from the same period last year. The company reported $31.47 million in

ACOR

Read More
2 minute read
  • Contracts
  • News

Acorda Therapeutics Announces New Agreement With Catalent For Long-Term Global Supply Of INBRIJA

By Benzinga Newsdesk
January 5, 5:20 PM
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent for the manufacture of INBRIJA (levodopa inhalation powder) at its

ACOR

Read More
6 minute read
  • Guidance
  • News

Acorda Therapeutics Announces Revised Long-Term Financial Guidance

By Benzinga Newsdesk
December 22, 9:04 AM
Key Assumptions Underlying Business Plan and Guidance Remain Unchanged INBRIJA will continue to grow in the U.S. INBRIJA will expand into additional ex-U.S. markets AMPYRA will continue to lose market

ACOR

Read More
1 minute read
  • News

Acorda Therapeutics Receives Nasdaq Listing Determination Letter, Plans To Request Hearing

By Michael Horton
December 20, 6:30 PM
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Company's common stock not having regained compliance

ACOR

Read More
1 minute read
  • News
  • Stock Split

Acorda Therapeutics Announces Passage Of ~2.5:1 Reverse Stock Split Proposal At Special Meeting of Stockholders

By Benzinga Newsdesk
November 11, 10:56 AM
"We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one. Authorizing our board to implement a reverse stock split is an important tool, if needed, to ensure that

ACOR

Read More
2 minute read
  • Short Ideas
  • Short Sellers
  • Trading Ideas

How Is The Market Feeling About Acorda Therapeutics?

By Benzinga Insights
November 9, 4:06 PM
Acorda Therapeutics's (NASDAQ:ACOR) short percent of float has risen 230.3% since its last report. The company recently reported that it has 792 thousand shares sold short, which is 3.27% of all regular shares that are available for trading.

ACOR

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights
November 1, 2:10 PM
Gainers

ABMD

Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday

By Lisa Levin
November 1, 3:31 AM
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.

ACOR

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights
October 31, 2:00 PM
Gainers

ACOR

Posts navigation

1 2 … 4 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service